NHI coverage extension for Zelmac in combined therapy.
Novartis Korea said that Zelmac (tagaserod hydrogen maleate) was a first and unique drug for the treatment of irritable bowel syndrome (IBS) approved by the U. S. ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
